

1 *Burkholderia pseudomallei* clinical isolates are highly susceptible *in vitro* to
2 cefiderocol, a novel siderophore cephalosporin

3 Delaney Burnard^{1,6}, Gemma Robertson^{1,2,4}, Andrew Henderson^{1,5}, Caitlin Falconer¹, Michelle
 4 Bauer-Leo¹, Kyra Cottrell¹, Ian Gassie^{2,3}, Robert Norton^{8,9}, David L. Paterson^{1,3}, Patrick N.
 5 A. Harris^{1,2*}

6

7 ¹University of Queensland Centre for Clinical Research, Herston, Queensland, Australia

8 ²Pathology Queensland, Queensland Health, Herston, Queensland, Australia

9 ³Royal Brisbane and Women's Hospital, Queensland Health, Herston, Queensland, Australia

10 ⁴Forensic and Scientific Services, Queensland Health, Coopers Plains, Queensland, Australia

11 ⁵Princess Alexandra Hospital, Queensland Health, Woolloongabba, Queensland, Australia

12 ⁶Genecology Research Centre, University of the Sunshine Coast, Sippy Downs, Queensland, Australia

13 ⁸Townsville Hospital and Health Service, Townsville, Queensland, Australia

14 ⁹School of Medicine, James cook university, Townsville, Queensland, Australia

15

16 *Corresponding author: p.harris@uq.edu.au

17 University of Queensland, Faculty of Medicine, UQ Centre for Clinical Research, Royal Brisbane & Women's
 18 Hospital, Herston, QLD, 4029, Australia

19

20 **Running title:** *B. pseudomallei* in vitro susceptibility to cefiderocol

21 **Keywords:** melioidosis, *Burkholderia pseudomallei*, cefiderocol, antimicrobial resistance,
 22 AMR, minimum inhibitory concentration, MIC

23 Abstract

24 Cefiderocol is a novel cephalosporin designed to treat multidrug resistant Gram-negative
 25 infections. By forming a chelated complex with ferric iron, cefiderocol is transported into the
 26 periplasmic space via bacterial iron transport systems and primarily binds to penicillin-
 27 binding protein 3 (PBP3) to inhibit peptidoglycan synthesis. This mode of action results in
 28 cefiderocol having greater *in vitro* activity against many Gram-negative bacilli than currently
 29 used carbapenems, β -lactam/ β -lactamase inhibitor combinations, and cephalosporins. Thus,
 30 we investigated the *in vitro* activity of cefiderocol (S-649266) against a total of 271 clinical
 31 isolates of *Burkholderia pseudomallei* from Australia. The collection was comprised of
 32 primary isolates (92.3%) and subsequent isolates (7.7%). Minimum inhibitory concentrations
 33 (MIC) of cefiderocol ranged from ≤ 0.03 to 32 mg/L, where the MIC₉₀ was 1 mg/L and 16
 34 mg/L for primary and subsequent isolates, respectively. Based upon non-species specific
 35 (Gram-negative bacilli) clinical breakpoints for cefiderocol (MIC ≤ 4 mg/L), twelve isolates
 36 (4.4%) would be classified as non-susceptible. Further testing for co-resistance to
 37 meropenem, ceftazidime, trimethoprim-sulfamethoxazole, amoxicillin-clavulanate and
 38 doxycycline was performed on a subset of isolates with elevated cefiderocol MICs (≥ 2 mg/L,
 39 4.8%) and 84.6% of these isolates exhibited resistance to at least one of these antimicrobials.
 40 Cefiderocol was found to be highly active *in vitro* against *B. pseudomallei* primary clinical
 41 isolates. This novel compound shows great potential for the treatment of melioidosis in
 42 endemic countries and should be explored further.

43 Introduction

44 Pathogenic multidrug-resistant (MDR) and carbapenem-non-susceptible Gram-negative
45 bacilli (GNB) have expanded significantly worldwide^{1,2}, diminishing appropriate
46 antimicrobial therapy options^{3,4}. Cefiderocol (formerly S-649266, Shionogi & Co. Ltd.,
47 Osaka, Japan) inhibits peptidoglycan synthesis, and has been described as almost
48 ubiquitously stable against β -lactamases, resulting in greater efficacy than carbapenems,
49 currently available β -lactam/ β -lactamase inhibitor combinations and cephalosporins⁵⁻⁸.

50 Cefiderocol recently received FDA approval for the treatment of complicated urinary tract
51 infections⁹, on the basis of non-inferiority against imipenem/cilastatin¹⁰. A trial versus
52 meropenem for nosocomial pneumonia has also been completed^{5,11} with efficacy
53 demonstrated against Gram-negative pathogens such as Enterobacterales, *Pseudomonas*
54 *aeruginosa* and *Acinetobacter baumannii*^{12,13}. Provisional CLSI *in vitro* breakpoints have
55 been set at ≤ 4 mg/L (S) and ≥ 16 mg/L (R) respectively for these pathogens¹². Furthermore,
56 cefiderocol has shown promising efficacy against *Burkholderia pseudomallei* and *B. mallei* in
57 limited sample sizes ($n = 30$), in the recommended Iron-depleted cation-adjusted Mueller-
58 Hinton broth (ID-CAMHB) (MIC₉₀ 0.25, 4 mg/L), respectively¹⁴.

59 *B. pseudomallei* is endemic to tropical and sub-tropical regions, including south-east Asia and
60 northern Australia and suspected for Africa and South America¹⁵⁻¹⁷. The bacteria is known
61 to cause melioidosis, where pneumonia, sepsis, neurological disease and visceral abscesses
62 are commonly described clinical presentations^{15,18}. Treatment for *B. pseudomallei* infections
63 require an “intensive” 2-8-week intravenous treatment with an antimicrobial such as a
64 carbapenem or cephalosporin, then followed by and orally administered “eradication”
65 treatment for 3-6 months with an antimicrobial such as trimethoprim-sulfamethoxazole¹⁹.
66 Infections frequently require intensive care admission and are associated with significant

67 morbidity²⁰. This is, in part due to the intrinsic antimicrobial resistance (AMR) of *B.*
68 *pseudomallei*, as well as acquired resistance to antimicrobials such as tetracyclines, β -
69 lactam/ β -lactamase inhibitors and rarely carbapenems^{21–23}. The mortality rate for patients
70 presenting with melioidosis ranges from 10-30% in Burma, Singapore, Thailand and
71 Vietnam²⁰, while in Australia it remains approximately 10%²⁴. Recent research has focused
72 on new or repurposed compounds in order to provide improved treatment options for such
73 infections, particularly given the potential of *B. pseudomallei* to be genetically manipulated
74 or used as an agent of biologic warfare^{25,26}. Therefore, with the need for new treatment
75 options for *B. pseudomallei* and other GNB, and promising efficacy of cefiderocol as a
76 treatment option, the aim of this study was to assess the *in vitro* activity of cefiderocol against
77 a large sample size of clinical *B. pseudomallei* isolates from endemic regions of Australia.

78 **Methods**

79

80 *Ethics*

81 Ethical approval for this study was granted by the Forensic and Scientific Services Human
82 Ethics Committee (HREC/17/QFSS/12). Biosafety approvals for this study were granted by
83 the Institutional Biosafety Committee UQCCR (IBC/210B/SOM/2017). This project was
84 performed under the study number: S-649266-EF-312-N.

85

86 *Isolates*

87 Clinical *B. pseudomallei* isolates were prospectively collected from patients admitted to
88 Queensland Health hospitals, Australia, over a period from 1999 to 2018. A small number of
89 isolates were referred from external laboratories. These isolates were retrieved from -80°C
90 storage from three microbiology laboratories in Queensland (Forensic and Scientific
91 Services, Coopers Plains; Pathology Queensland, Townsville and Central laboratories).
92 Isolates were transferred to the University of Queensland Centre for Clinical Research
93 (UQCCR) and stored at stored at -80°C prior to testing. Demographic and clinical
94 information for the isolates and patients was retrieved from the laboratory information system
95 (Auslab; PJA Solutions).

96 *Disc Diffusion*

97 Disc diffusion susceptibility testing was performed using 30 µg cefiderocol discs provided by
98 Mast Group Ltd. (Bootle, UK). Discs were stored at 4°C prior to use. Isolates were sub-
99 cultured from storage on 5% horse blood agar (Micromedia, Victoria, Australia) for 18-24h at
100 37°C prior to preparation of a 0.5 McFarland solution in 0.9% sterile saline. Mueller-Hinton

agar plates (Micromedia, Victoria, Australia) were inoculated with test isolates using the Kirby-Bauer method and incubated for 16- 20h at 37°C. Control strains *E. coli* ATCC 25922 and *P. aeruginosa* ATCC 27853 were included with each run.

Broth Microdilution

Broth microdilution (BMD) was performed using 96-well plates provided by Shionogi & Co., Ltd. (Osaka, Japan) and prepared by International Health Management Associates (IHMA; Schaumburg, USA). Iron-depleted cation-adjusted Mueller-Hinton broth (ID-CAMHB) was used according to CLSI and manufacturer recommendations²⁷. Plates were stored at -20°C and thawed for one hour prior to use. Isolates were sub-cultured from storage on to 5% horse blood agar (Micromedia, Victoria, Australia) for 18-24h at 37°C prior to preparation of a 0.5 McFarland solution in 0.9% sterile saline for a final inoculum of 5×10^5 . A maximum of three plates were inoculated and then sealed during each run, owing to biosecurity restrictions. Plates were incubated at 37°C for 16 to 20h prior to reading. One positive growth control well and one negative control well were included in each plate. Quality control of cefiderocol was performed using *E. coli* ATCC 25922 and *P. aeruginosa* ATCC 27853 strains, with only those runs that passed QC and with appropriate growth in the positive control included for analysis²⁸. CLSI provides susceptible (≤ 4 mg/L) and resistant (≥ 16 mg/L) interpretative criteria for Enterobacterales and some non-fermenters such as *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Stenotrophomonas maltophilia* (but not *B. pseudomallei*)¹². As such, these breakpoints were applied to isolates in this study.

Further antimicrobial susceptibility testing was performed on isolates with elevated cefiderocol MICs, for meropenem, ceftazidime, doxycycline, amoxicillin-clavulanic acid and

125 trimethoprim-sulfamethoxazole. BMD was performed in house where 96 well plates were
 126 prepared using the Tecan D300e Digital Dispenser (HP Inc. CA, USA.) Standard inoculum
 127 (5×10^5 CFU), incubation in ambient air at 37°C and end point reading at 24 hours were
 128 performed. Quality control was performed in duplicate for each batch of plates made
 129 including *E. coli* ATCC 25922, *E. coli* ATCC 35218 and *S. aureus* ATCC 29213 to ensure
 130 correct dilutions of each antimicrobial²⁸. The range of meropenem, ceftazidime, doxycycline,
 131 amoxicillin-clavulanic acid and trimethoprim-sulfamethoxazole tested was 0.06-16, 0.06-16,
 132 0.12-16, 0.12/2-32/2 and 0.06/1.19-32/608 mg/L, respectively. MICs were interpreted
 133 according to CLSI breakpoints²⁹.

Results

Isolates

A total of 271 isolates from 250 individuals were included in this study (Table 1a &b). Multiple isolates from 15 patients were identified and separated into primary (n=250) and subsequent (n=21) isolate test groups. Subsequent isolates comprised of duplicate specimens, specimens collected from an alternate anatomical site or isolates collected weeks, months or years apart. The antimicrobial treatment of patients is unknown. From the 250 individuals, *B. pseudomallei* was predominantly isolated from males and blood, lung, skin and soft tissue specimens (Table 1a & b). All isolates were from Queensland with the exception of one from New South Wales, two from the Northern Territory, two from South Australia and one from Tasmania. International isolates included: one each from England and Germany, two from New Zealand and two from Papua New Guinea.

Disc diffusion

All 271 isolates were subject to disc diffusion testing. Zone diameters ranged from 14-46 mm and 11-43 mm for primary and subsequent isolates, respectively (Table 2). Two isolates C137 (38 mm) and T62 (41 mm) demonstrated inner growth on disc diffusion testing (12 mm and 17 mm respectively), indicating a heterogeneous population or expression.

Broth Microdilution

Cefiderocol BMD was performed on all 271 isolates. For primary isolates the MIC range, MIC₅₀, and MIC₉₀ were ≤0.03-8, 0.06 and 1 mg/L, while the corresponding values for

subsequent isolates were ≤ 0.03 -32, 0.25 and 16 mg/L (Table 2, Figure 1). Significant differences between zone diameter and MIC were only observed for MIC values ≥ 8 mg/L, in both isolate groups (Figure 2).

Isolates expressing elevated cefiderocol minimum inhibitory concentrations

According to CLSI breakpoints for cefiderocol against other GNB, 8 isolates (2.9%) would be categorised as non-susceptible (≥ 8 mg/L). However, our data displayed a tri-modal distribution (Figure 1) where isolates with MICs ≥ 2 mg/L represented the 2.5% of isolates with the highest MICs. This included four isolates at 4 mg/L, one at 2 mg/L and 8 isolates with MICs ≥ 8 mg/mL, resulting in 13 isolates (4.8%) being considered to have elevated MICs (i.e ≥ 2 mg/L) in this study. The 13 isolates (4.8%) with elevated cefiderocol MICs were comprised of 46.1% primary and 53.9% subsequent isolates, predominantly collected from the lung (53.9%) and individuals with serious underlying co-morbidities (92.3%) (Table 3). Co-resistance was examined via BMD between cefiderocol and meropenem, ceftazidime, amoxicillin clavulanic acid, doxycycline, and trimethoprim-sulfamethoxazole; with 11 of the 13 isolates (84.6%) also resistant to amoxicillin-clavulanic acid. Resistance to the other antimicrobials tested was observed, yet inconsistently (Table 3, Figure 3).

Discussion

B. pseudomallei infections pose a significant mortality risk to patients. Furthermore, treatment can be especially burdensome in terms of the need for prolonged intravenous and oral antibiotic therapy. Due to the virulence of the organism, and its predilection for immune compromised hosts, patients with melioidosis frequently present with severe disease requiring intensive care admission. While uncommon, emergent resistance may also occur to compromise treatment. A novel compound such as cefiderocol with such low MICs, could be used as an empirical therapy to improve clinical outcomes of *B. pseudomallei* in endemic regions, where multi-drug resistant Gram-negative bacilli are circulating. An approach such as this, may result in improved clinical responses during empirical therapy and increased bacterial killing in hard to treat infections like those in the central nervous system, bone, joint and lymphatic system.

Disc diffusion

The relationship between cefiderocol disc diffusion zone diameter and BMD MIC values was observed at concentrations ≥ 8 mg/L of cefiderocol. As there are no zone diameters specified for cefiderocol disc diffusion against *B. pseudomallei* very major errors, major errors and minor errors were unable to be calculated. Zone diameter was able to differentiate resistant (≥ 8 mg/L) isolates consistently at less than 25mm (Figure 2). This relationship was previously observed in over 1,300 Gram-negative bacteria where resistant isolates (≥ 8 mg/L) were consistently differentiated at 20 mm or less³⁰. These relationships were present in species such as Enterobacteriaceae, *P. aeruginosa* and *A. baumannii*, however *S. maltophilia* isolates (≥ 2 mg/L) were differentiated at 15 mm or less³⁰. Better discrimination among

susceptible isolates may be seen with a lower disk mass, but only 30 µg disks are currently available commercially.

Broth microdilution

In this study isolates with MIC values ≥ 2 mg/L were considered to have elevated cefiderocol MICs, yet few were identified in this collection ($n=13$). This finding is expected, with previous *in vitro* studies identifying very few resistant isolates for several Gram-negative bacilli species, for example only 24/753 isolates showed MICs ≥ 8 mg/L from a global dataset³¹, 54/8954 isolates had MICs ≥ 4 mg/L¹³ and no resistant isolates were identified among 189 isolates from Greece³². *In vitro* MIC₉₀ values of the 250 primary *B. pseudomallei* isolates was 1 mg/L in this study, higher than the previously described MIC₉₀ of 0.25 mg/L obtained from a pilot study of 30 *B. pseudomallei* isolates¹⁴. The increase in MIC may be influenced by the increase in sample size, however larger samples sizes have not substantially increased the MIC₉₀ of cefiderocol in other pathogens such as *P. aeruginosa*, *A. baumannii*, *K. pneumoniae* and *E. coli*^{13,31,32}. Moreover, sister species *B. mallei* has an MIC₉₀ of 4 mg/L from 30 isolates, significantly higher than that observed in *B. pseudomallei*¹⁴, whereas isolates from the closely related *B. cepacia* complex also exhibit a consistently low MIC₉₀ of 0.016 and 0.12 mg/L, despite small sample sizes in ID-CAMHB media^{5,13}.

Isolates with elevated cefiderocol minimum inhibitory concentrations

As no patient had received cefiderocol previously, we expect the MIC increase is likely a reflection of including isolates from complex patients with persistent or relapsing infection. Subsequent isolates exhibited an exceptionally high MIC₉₀ of 16 mg/L with 84.6% of these isolates originating from patients with underlying conditions. Six isolates C50 and 52 (4

mg/L) and C4, 5, 6, and 7 (8 mg/L) were derived from the sputum of a patient with cystic fibrosis or prolonged chronic *B. pseudomallei* lung colonisation. These isolates have been exposed to significant and prolonged treatment with antimicrobials, representing and influencing 46.1% of the isolates with elevated cefiderocol MICs observed. Furthermore, five isolates C15, C137R, C194, T18 and T63 were derived from patients with immunosuppression following organ transplantation or poorly controlled diabetes, representing and influencing 38.5% of *B. pseudomallei* isolates with elevated cefiderocol MICs. Clinical data was not available for the remaining two isolates. Our results predict elevated cefiderocol MICs will more than likely be encountered in individuals with prolonged or extensive antimicrobial exposure, in conjunction with persistent or relapsing *B. pseudomallei* infections.

Five clinically relevant antimicrobials were selected for further BMD testing against *B. pseudomallei* isolates with elevated cefiderocol MICs, to assess the presence of co-resistance. Interestingly, 84.6% of the 13 isolates exhibited resistance to amoxicillin-clavulanic acid, followed by 38.5% with non-susceptibility to ceftazidime, 30.8% with trimethoprim-sulfamethoxazole resistance and 23% with meropenem and doxycycline resistance, respectively. These rates of resistance are much higher than those reported from Australia (0.0-4.0%) in previous studies³³⁻³⁵. Subsequent isolate C5 exhibited a multidrug resistant profile with resistance to meropenem, amoxicillin-clavulanic acid, trimethoprim-sulfamethoxazole, doxycycline, non-susceptibility to ceftazidime and a cefiderocol MIC of 8 mg/L. Previous studies have highlighted that cefiderocol activity is not generally impacted by resistance to other antimicrobials^{5-7,13,32}. In this study, amoxicillin-clavulanic acid resistance does not appear to impact cefiderocol or ceftazidime MICs. As these isolates are from individuals with known antimicrobial exposure and significant co-morbidities, it is less likely

that elevated cefiderocol MICs reflect co-resistance, and is more likely a result of exposure and adaptation.

Prospective role of cefiderocol against B. pseudomallei infections

Cefiderocol has great potential as antimicrobial therapy for multi-drug resistant *B. pseudomallei* infections. This is supported by the findings of this study, in combination with the efficacy of cefiderocol being unaffected by resistance to other antimicrobials *in vitro*³², the antimicrobial being well tolerated by patients^{5,8} and found to be safe in clinical trials to date⁸. However, this study also suggests that cefiderocol may lose efficacy *in vitro* against *B. pseudomallei* isolates derived from individuals with significant underlying co-morbidities and prolonged antibiotic exposure. Nevertheless, further *in vitro* testing, followed by *in vivo* trials of cefiderocol against *B. pseudomallei* is certainly validated.

Conclusion

Cefiderocol demonstrates a high degree of activity *in vitro* against clinical isolates of *B. pseudomallei* from Australia. The MIC₅₀ and MIC₉₀ are 0.06 and 1 mg/L, respectively. Elevated cefiderocol MICs were infrequently demonstrated in this collection (4.8%) based on non-species-specific breakpoints and is most commonly associated with significant underlying co-morbidities. Cefiderocol shows promise as an intravenous agent for the management of acute melioidosis based upon *in vitro* susceptibility testing, particularly in regions where carbapenem-resistant Gram-negative organisms and *B. pseudomallei* co-circulate. Further investigation into the role of cefiderocol as a treatment for melioidosis and likely mechanisms of resistance would be of great value.

284 **Acknowledgements**

285 The authors would like to acknowledge the ongoing and financial support of Shionogi & Co.,
286 LTD., under the stand-alone service agreement. Additionally, the authors would like to
287 acknowledge the efforts of Pathology Queensland collaborators: Haakon Bergh and Tracey
288 Shepherd during this study.

289

290

291

292

293

294

295

296

297

298

299

300

Table 1a. Demographic and clinical data for primary *B. pseudomallei* isolates.

<i>Individuals</i>		
	<i>n</i> patients	250
	Age range	6-90 years
	Gender	26.4% F, 73.6% M
<i>Isolate collection site</i>		
	Blood	135
	Lung	31
	Skin and soft tissue	27
	Urine	14
	Sputum	11
	Unknown	6
	Bone/joint	5
	Liver	2
	Synovial fluid	2
	Prostate	1
	Brain	1
	Lymph node	1
	Gastrointestinal tract	1
	Gut	1
	Pleural fluid	1
	Peritoneal fluid	1
<i>Isolate total</i>	<i>n</i>	250

Table 1b. Demographic and clinical data for secondary and subsequent *B. pseudomallei* isolates.

<i>Individuals</i>		
	<i>n</i> patients	15
	Age range	10-74 years
	Gender	53.3% F, 46.6% M
<i>Isolate collection site</i>		
	Lung	8
	Blood	5
	Skin and soft tissue	4
	Unknown	2
	Bone/joint	1
<i>Isolate total</i>	<i>n</i>	21

308 Table 2. *In vitro* minimum inhibitory concentrations (mg/L) and disc diffusion range (mm)
309 for both primary and subsequent *B. pseudomallei* isolates against cefiderocol.

Isolates	Cefiderocol MIC (mg/L)												Disc Zone		
	≤0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	≥32	Range	MIC ₅₀	MIC ₉₀	(mm)
Primary (n=250)	72	93	0	13	32	35	0	3	1	1	0	≤0.03-8	0.06	1	14-46
Subsequent (n=21)	6	4	0	1	2	0	1	1	4	1	1	≤0.03-32	0.25	16	11-43

310

311

312

313

314

315

Table 3. Minimum inhibitory concentrations of *B. pseudomallei* isolates with elevated cefiderocol (CEF) concentrations against meropenem (MEM), ceftazidime (CAZ), amoxicillin-clavulanic (AMZ) acid, trimethoprim-sulfamethoxazole (SXT) and doxycycline (DOX). Non-susceptible and resistant categories are denoted with NS or R, respectively. Isolates from individuals with underlying co-morbidities are noted.

<i>B. pseudomallei</i> isolate	Site collected	Underlying co-morbidity	Clinically relevant antimicrobials (mg/L)					
Primary			CEF	MEM	CAZ	AMC	SXT	DOX
C4	Lung	Yes	8	□16 R	2	□32 R	0.12/2.28	2
T17	Blood	Unknown	4	2	≥ 16 NS	□32 R	0.25/4.75	≥16 R
T18	Blood	Yes	2	2	4	□32 R	0.12/2.28	1
C50	Lung	Yes	4	4	≥ 16 NS	□32 R	4/76 R	4
T63	Sputum	Yes	4	1	4	□32 R	0.12/2.28	8
C194	Blood	Yes	16	□ 16 R	2	□32 R	0.12/2.28	2
Subsequent			CEF	MEM	CAZ	AMC	SXT	DOX
C5	Lung	Yes	8	□ 16 R	□ 16 NS	□32 R	16/304 R	□16 R
C6	Lung	Yes	8	1	□ 16 NS	4	0.12/2.28	8
C7	Lung	Yes	8	4	1	4	0.12/2.28	8
C15	Lung	Yes	8	1	2	32 R	16/304 R	16 R
C52	Lung	Yes	4	4	□ 16 NS	□32 R	4/76 R	4
T62R	SSTI	Unknown	32	1	4	□32 R	0.25/4.75	2
C137R	SSTI	Yes	16	1	2	□32 R	0.5/9.5	2




Figure 1. Stacked histogram of cefiderocol minimum inhibitory concentrations (mg/L) for 271 clinical *Burkholderia pseudomallei* isolates. Primary isolates collected are shown in light blue, while subsequent isolates are shown in dark blue.




Figure 2. Scatterplot of cefiderocol disc zone diameters (mm) vs cefiderocol minimum inhibitory concentrations (mg/L) for 271 clinical *Burkholderia pseudomallei* isolates. Primary isolates collected are shown in blue, while subsequent isolates are shown in red.




Figure 3. Stacked histogram of cefiderocol minimum inhibitory concentrations (mg/L) against categorised amoxicillin-clavulanic acid (AMC), ceftazidime (CAZ), doxycycline (DOX), meropenem (MEM) and trimethoprim-sulfamethoxazole (SXT) minimum inhibitory concentrations (mg/L) for *Burkholderia pseudomallei* isolates with cefiderocol MIC values of 2 mg/L or greater.

References

1. Tacconelli, E. *et al.* Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect. Dis.* **18**, 318–327 (2018).
2. World Health Organization. Antimicrobial resistance global report on surveillance. (2014) doi:<http://www.who.int/drugresistance/documents/surveillancereport/en/>.
3. Boucher, H. W. *et al.* Bad Bugs, No Drugs: No ESCAPE! An Update from the Infectious Diseases Society of America. *Clin. Infect. Dis.* **48**, 1–12 (2009).
4. Hawkey, P. M. *et al.* Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. *J. Antimicrob. Chemother.* **73**, iii2–iii78 (2018).
5. Zhanel, G. G. *et al.* Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. *Drugs* **79**, 271–289 (2019).
6. Ito, A. *et al.* Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* **60**, 7396–7401 (2016).
7. Ito, A. *et al.* In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria. *Antimicrob. Agents Chemother.* **62**, (2017).
8. Saisho, Y., Katsube, T., White, S., Fukase, H. & Shimada, J. Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects. *Antimicrob. Agents Chemother.* **62**, e02163-17 (2018).

9. Shionogi & Co., Ltd. Press Release: FETROJA® (cefiderocol) Approved by the FDA for Treatment of Complicated Urinary Tract Infections (cUTI) in Adult Patients with Limited or No Alternative Treatment Options.
(doi:<http://www.shionogi.co.jp/en/company/news/2019/>)
10. Portsmouth, S. *et al.* Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. *Lancet Infect. Dis.* **18**, 1319–1328 (2018).
11. Masakatsu Tsuji & LTC Charles L Marchand, C. J. Cefiderocol (S-649266), a Novel Siderophore Cephalosporin: In Vitro Activity against Biothreat Pathogens. Poster presented at: ID Week; 2016 October 26-30; New Orleans, USA.
12. CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests. 13th ed. CLSI standard M02. Wayne, PA: Clinical and Laboratory Standards Institute; 2018. in.
13. Karlowsky, J. A. *et al.* In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. *Int. J. Antimicrob. Agents* **53**, 456–466 (2019).
14. Tsuji, M., Jakielaszek, C. & Marchand, L. C. L. S-649266, a Novel Siderophore Cephalosporin: In Vitro Activity Against Biothreat Pathogen. *Open Forum Infect. Dis.* **3**, (2016).
15. Cheng, A. C. & Currie, B. J. Melioidosis: Epidemiology, Pathophysiology, and Management. *Clin. Microbiol. Rev.* **18**, 383–416 (2005).
16. McRobb, E. *et al.* Distribution of *Burkholderia pseudomallei* in Northern Australia, a Land of Diversity. *Appl Env. Microbiol* **80**, 3463–3468 (2014).
17. Limmathurotsakul, D. *et al.* Predicted global distribution of *Burkholderia pseudomallei* and burden of melioidosis. *Nat. Microbiol.* **1**, (2016).

- 391 18. Hemarajata, P., Baghdadi, J. D., Hoffman, R. & Humphries, R. M. *Burkholderia*
392 *pseudomallei*: Challenges for the Clinical Microbiology Laboratory. *J. Clin. Microbiol.*
393 **54**, 2866–2873 (2016).
- 394 19. Wiersinga, W. J., Currie, B. J. & Peacock, S. J. Melioidosis. *N. Engl. J. Med.* **367**, 1035–
395 1044 (2012).
- 396 20. Perumal Samy, R., Stiles, B. G., Sethi, G. & Lim, L. H. K. Melioidosis: Clinical impact
397 and public health threat in the tropics. *PLoS Negl. Trop. Dis.* **11**, (2017).
- 398 21. Rhodes, K. A. & Schweizer, H. P. Antibiotic resistance in *Burkholderia* species. *Drug*
399 *Resist. Updat.* **28**, 82–90 (2016).
- 400 22. Schweizer, H. P. Mechanisms of antibiotic resistance in *Burkholderia pseudomallei*:
401 implications for treatment of melioidosis. *Future Microbiol.* **7**, 1389–1399 (2012).
- 402 23. Wuthiekanun, V. *et al.* Survey of Antimicrobial Resistance in Clinical *Burkholderia*
403 *pseudomallei* Isolates over Two Decades in Northeast Thailand. *Antimicrob. Agents*
404 *Chemother.* **55**, 5388–5391 (2011).
- 405 24. Currie, B. J., Dance, D. A. B. & Cheng, A. C. The global distribution of *Burkholderia*
406 *pseudomallei* and melioidosis: an update. *Trans. R. Soc. Trop. Med. Hyg.* **102**, S1–S4
407 (2008).
- 408 25. Ross, B. N., Myers, J. N., Muruato, L. A., Tapia, D. & Torres, A. G. Evaluating New
409 Compounds to Treat *Burkholderia pseudomallei* Infections. *Front. Cell. Infect.*
410 *Microbiol.* **8**, (2018).
- 411 26. Laws, T. R., Taylor, A. W., Russell, P. & Williamson, D. The treatment of melioidosis: is
412 there a role for repurposed drugs? A proposal and review. *Expert Rev. Anti Infect. Ther.*
413 **0**, 1–11 (2019).

- 414 27. Huband, M. D. *et al.* Cefiderocol MIC quality control ranges in iron-depleted cation-
415 adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design.
416 *Diagn. Microbiol. Infect. Dis.* **88**, 198–200 (2017).
- 417 28. Kahlmeter, G. *et al.* European Committee on Antimicrobial Susceptibility Testing
418 (EUCAST) Technical Notes on antimicrobial susceptibility testing. *Clin. Microbiol.*
419 *Infect.* **12**, 501–503 (2006).
- 420 29. Clinical and Laboratory Standards Institute. CLSI guideline M45. Methods for
421 Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or
422 Fastidious Bacteria. 3rd ed, Wayne, PA: Clinical and Laboratory Standards Institute;
423 2016.
- 424 30. Masakatsu Tsuji, M. H., Yoshinori Yamano, N. K. & Daniel F Sahm, R. E. Correlations
425 between Cefiderocol Broth Microdilution MICs and Disk Diffusion Inhibitory Zone
426 Diameters among Target Gram-Negative Organisms. Poster presented at: 28th ECCMID;
427 2018 April 21-24; Madrid, Spain.
- 428 31. Dobias, J., Dénervaud-Tendon, V., Poirel, L. & Nordmann, P. Activity of the novel
429 siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative
430 pathogens. *Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol.* **36**,
431 2319–2327 (2017).
- 432 32. Falagas, M. E., Skolidis, T., Vardakas, K. Z. & Legakis, N. J. Activity of cefiderocol (S-
433 649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients
434 in Greek hospitals. *J. Antimicrob. Chemother.* **72**, 1704–1708 (2017).
- 435 33. Crowe, A., McMahon, N., Currie, B. J. & Baird, R. W. Current antimicrobial
436 susceptibility of first-episode melioidosis *Burkholderia pseudomallei* isolates from the
437 Northern Territory, Australia. *Int. J. Antimicrob. Agents* **44**, 160–162 (2014).

- 438 34. Smith, S., Hanson, J. & Currie, B. J. Melioidosis: An Australian Perspective. *Trop. Med.*
439 *Infect. Dis.* **3**, 27 (2018).
- 440 35. Jenney, A. W. J., Lum, G., Fisher, D. A. & Currie, B. J. Antibiotic susceptibility of
441 *Burkholderia pseudomallei* from tropical northern Australia and implications for therapy
442 of melioidosis. *Int. J. Antimicrob. Agents* **17**, 109–113 (2001).
- 443